Abstract P1-18-21: Neratinib reduces HER2+/luminal B breast cancer stem cell activity and inhibits resistance by blocking efflux mechanisms
Authors: Nathan Hull, Robert Clarke, Nigel Bundred
Published: 2020-03-26
DOI:
10.1158/1538-7445.sabcs19-p1-18-21
Source:
Full article
Abstract
Abstract